149 related articles for article (PubMed ID: 27911011)
41. Design, synthesis and preliminary bioactivity studies of 2-thioxo-4-thiazolidinone derivatives as Bcl-2 inhibitors.
Wan Y; Wu S; Xiao G; Liu T; Hou X; Chen C; Guan P; Yang X; Fang H
Bioorg Med Chem; 2015 May; 23(9):1994-2003. PubMed ID: 25818766
[TBL] [Abstract][Full Text] [Related]
42. Identification of Small-Molecule Inhibitors of the Antiapoptotic Protein Myeloid Cell Leukaemia-1 (Mcl-1).
Beekman AM; O'Connell MA; Howell LA
ChemMedChem; 2016 Apr; 11(8):840-4. PubMed ID: 26616140
[TBL] [Abstract][Full Text] [Related]
43. Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors.
Wan Y; Wang J; Sun F; Chen M; Hou X; Fang H
Bioorg Med Chem; 2015 Dec; 23(24):7685-93. PubMed ID: 26620718
[TBL] [Abstract][Full Text] [Related]
44. Bicyclic Helical Peptides as Dual Inhibitors Selective for Bcl2A1 and Mcl-1 Proteins.
D de Araujo A; Lim J; Wu KC; Xiang Y; Good AC; Skerlj R; Fairlie DP
J Med Chem; 2018 Apr; 61(7):2962-2972. PubMed ID: 29584430
[TBL] [Abstract][Full Text] [Related]
45. Structural Re-engineering of the α-Helix Mimetic JY-1-106 into Small Molecules: Disruption of the Mcl-1-Bak-BH3 Protein-Protein Interaction with 2,6-Di-Substituted Nicotinates.
Drennen B; Scheenstra JA; Yap JL; Chen L; Lanning ME; Roth BM; Wilder PT; Fletcher S
ChemMedChem; 2016 Apr; 11(8):827-33. PubMed ID: 26844930
[TBL] [Abstract][Full Text] [Related]
46. Drimane Derivatives as the First Examples of Covalent BH3 Mimetics that Target MCL-1.
Daressy F; Malard F; Seguy L; Guérineau V; Apel C; Dumontet V; Robert A; Groo AC; Litaudon M; Bignon J; Desrat S; Malzert-Fréon A; Wiels J; Lescop E; Roussi F
ChemMedChem; 2021 Jun; 16(11):1788-1797. PubMed ID: 33665938
[TBL] [Abstract][Full Text] [Related]
47. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
[TBL] [Abstract][Full Text] [Related]
48. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
49. Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition.
Song T; Chai G; Liu Y; Xie M; Chen Q; Yu X; Sheng H; Zhang Z
Eur J Pharm Sci; 2015 Apr; 70():64-71. PubMed ID: 25596561
[TBL] [Abstract][Full Text] [Related]
50. Probing the difference between BH3 groove of Mcl-1 and Bcl-2 protein: Implications for dual inhibitors design.
Zhang Z; Yang H; Wu G; Li Z; Song T; Li XQ
Eur J Med Chem; 2011 Sep; 46(9):3909-16. PubMed ID: 21684048
[TBL] [Abstract][Full Text] [Related]
51. Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins.
Tanaka Y; Aikawa K; Nishida G; Homma M; Sogabe S; Igaki S; Hayano Y; Sameshima T; Miyahisa I; Kawamoto T; Tawada M; Imai Y; Inazuka M; Cho N; Imaeda Y; Ishikawa T
J Med Chem; 2013 Dec; 56(23):9635-45. PubMed ID: 24215352
[TBL] [Abstract][Full Text] [Related]
52. Design, synthesis and biological evaluation of hydantoin derivatives as Mcl-1 selective inhibitors.
Liang X; Li X; Zhao Z; Nie Y; Yao Z; Ren W; Yang X; Hou X; Fang H
Bioorg Chem; 2022 Apr; 121():105643. PubMed ID: 35150958
[TBL] [Abstract][Full Text] [Related]
53. Discovery of novel indazole-acylsulfonamide hybrids as selective Mcl-1 inhibitors.
Wan Y; Li Y; Yan C; Wen J; Tang Z
Bioorg Chem; 2020 Nov; 104():104217. PubMed ID: 32911192
[TBL] [Abstract][Full Text] [Related]
54. Improved binding affinities of pyrrolidine derivatives as Mcl-1 inhibitors by modifying amino acid side chains.
Wan Y; Liu T; Li X; Chen C; Fang H
Bioorg Med Chem; 2017 Jan; 25(1):138-152. PubMed ID: 27810438
[TBL] [Abstract][Full Text] [Related]
55. Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.
Bruncko M; Wang L; Sheppard GS; Phillips DC; Tahir SK; Xue J; Erickson S; Fidanze S; Fry E; Hasvold L; Jenkins GJ; Jin S; Judge RA; Kovar PJ; Madar D; Nimmer P; Park C; Petros AM; Rosenberg SH; Smith ML; Song X; Sun C; Tao ZF; Wang X; Xiao Y; Zhang H; Tse C; Leverson JD; Elmore SW; Souers AJ
J Med Chem; 2015 Mar; 58(5):2180-94. PubMed ID: 25679114
[TBL] [Abstract][Full Text] [Related]
56. Structure-based virtual screening, biological evaluation and biophysical study of novel Mcl-1 inhibitors.
Du J; Liu L; Liu B; Yang J; Hou X; Yu J; Fang H
Future Med Chem; 2020 Jul; 12(14):1293-1304. PubMed ID: 32397829
[No Abstract] [Full Text] [Related]
57. Dual inhibitors of the pro-survival proteins Bcl-2 and Mcl-1 derived from natural compound meiogynin A.
Abou Samra A; Robert A; Gov C; Favre L; Eloy L; Jacquet E; Bignon J; Wiels J; Desrat S; Roussi F
Eur J Med Chem; 2018 Mar; 148():26-38. PubMed ID: 29453135
[TBL] [Abstract][Full Text] [Related]
58. Discovery of a Copper-Based Mcl-1 Inhibitor as an Effective Antitumor Agent.
Lu X; Liu YC; Orvig C; Liang H; Chen ZF
J Med Chem; 2020 Sep; 63(17):9154-9167. PubMed ID: 32794745
[TBL] [Abstract][Full Text] [Related]
59. Virtual screening, SAR, and discovery of 5-(indole-3-yl)-2-[(2-nitrophenyl)amino] [1,3,4]-oxadiazole as a novel Bcl-2 inhibitor.
Ziedan NI; Hamdy R; Cavaliere A; Kourti M; Prencipe F; Brancale A; Jones AT; Westwell AD
Chem Biol Drug Des; 2017 Jul; 90(1):147-155. PubMed ID: 28067996
[TBL] [Abstract][Full Text] [Related]
60. Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands.
Wang Z; He N; Guo Z; Niu C; Song T; Guo Y; Cao K; Wang A; Zhu J; Zhang X; Zhang Z
J Med Chem; 2019 Sep; 62(17):8152-8163. PubMed ID: 31389699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
